COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHw ...

The FDA has issued more than 200 complete response letters, which detail reasons for non-approval of drug applications.

Some of the new online resources debunk the more outlandish claims of government weather control.

The first phase of Fujifilm Biotechnologies’ $3.2-billion large-scale cell culture biopharmaceutical manufacturing plant in North Carolina is scheduled to begin operating this year.

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment o ...